Chemotherapy for Colorectal Cancer

@article{Goyle2005ChemotherapyFC,
  title={Chemotherapy for Colorectal Cancer},
  author={Sandeep Goyle and Anthony Maraveyas},
  journal={Digestive Surgery},
  year={2005},
  volume={22},
  pages={401 - 414}
}
Colorectal cancer is the most commonly diagnosed cancer in the EU. Various randomised studies have shown a survival benefit with chemotherapy in the adjuvant setting. Adjuvant chemotherapy with 5-fluorouracil/folinic acid (5FU/FA) for 6 months after curatively resected node-positive colon cancer has become the standard practice. However, controversy still exists regarding the optimal regimen and whether to treat node-negative patients. The latest QUASAR trial results seem to strengthen the… 
First-Line Treatment Strategies for Elderly Patients with Metastatic Colorectal Cancer
TLDR
Current optimal first-line treatment strategies for elderly patients with metastatic colorectal cancer are reviewed, with evidence that elderly individuals derive as much survival benefit from standard chemotherapy approaches in metastatic cancer as younger patients.
Novel Biomarker-Targeted Therapies for Metastatic Colorectal Cancer
TLDR
An overview of the different molecular subsets of CRC and the current biomarker-targeted therapies in the management of metastatic disease is provided.
Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM).
  • J. Evans
  • Medicine
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • 2007
Safety of Early Chemotherapy after a Laparoscopic Colorectal Cancer Resection: A Case-Control Study
TLDR
Because nausea is an easily controllable toxicity, it is concluded that chemotherapy is safely started on the 7th or the 8th day after a laparoscopic colorectal cancer resection.
Acupuncture and Moxibustion for Side Effects of Chemotherapy in Cancer Patients
This chapter introduces the major classes of chemotherapeutic drugs, including the alkylating agents, antimetabolites, vinca alkaloids, taxanes, antibiotics, hormone analogs and targeted drugs. The
The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles
TLDR
The current review aims to unravel the mechanisms by which the PI3K/Akt/mTOR pathway affects CRC progression; and to summarize the original data obtained from international research laboratories on the oncogenic alterations and polymorphisms affecting this pathway in CRC.
The anti-proliferative effect of apricot and peach kernel extracts on human colon cancer cells in vitro
TLDR
Abrogation of the block by exhaustion of the cyanide production, most likely allowed the cells to resume the cell cycle and continue into mitosis, whereas low ATP levels caused by the presence of amygdalin in the kernels, can also cause the induction of pycnosis or necrosis.
Acupuncture and Moxibustion as an Evidence-based Therapy for Cancer
TLDR
It was concluded that CINV and cancer pain are the only indications for acupuncture, acupressure or moxibustion currently supported by concrete evidence and future studies should be of high quality with a particular emphasis on designing adequate control interventions.
NEW [11C]PHOSGENE BASED SYNTHESIS OF 11C]PYRIMIDINES FOR POSITRON EMISSION TOMOGRAPHY
Thymine, 5-FU, and uracil were successfully synthesized through a procedure involving a cyclocondensation of triphosgene with newly developed α-substituted β-aminoacrylamides intermediates (la, X=
...
1
2
...

References

SHOWING 1-10 OF 134 REFERENCES
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
TLDR
Elderly patients with good performance status tolerated adjuvant and palliative chemotherapy for CRC as well as did younger patients and had similar benefits from palliatives chemotherapy.
Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report
TLDR
This is a mature study with all patients able to be followed for more than 5 years, and the evidence for therapeutic benefit was strong, but it was possible that the authors were only prolonging the interval to cancer recurrence and death rather than actually improving cure rates.
Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
TLDR
It is concluded that early treatment with MFL prolongs survival, the asymptomatic period, and the time to disease progression by approximately 6 months over primary expectancy.
QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients.
TLDR
Chemotherapy produces a small (1% - 5%) survival benefit for stage B patients, sufficient to outweigh the inconvenience and cost for high-risk and younger patients.
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
TLDR
Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.
  • C. Erlichman
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
This data set does not support the routine use of FU + LV in all patients with B2 Colon cancer, and studies in B2 colon cancer designed with a no-treatment control arm should be considered appropriate.
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
TLDR
The data suggest that 5-FU plus levamisole for 6 months should not be used in clinical practice, whereas 6 months of treatment with 5-fu plus leucovorin plus lev amisole is effective.
The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.
TLDR
Treating patients with Dukes' stage B and C carcinoma of the colon with leucovorin-modulated fluorouracil as adjuvant therapy significantly prolongs disease-free survival and results in a significant benefit relative to overall survival.
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.
  • P. Piedbois
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
TLDR
Tumor response should not be considered a valid surrogate end point for survival in patients with advanced colorectal cancer in future trials, according to a meta-analysis performed on nine randomized clinical trials.
...
1
2
3
4
5
...